{"id":538807,"date":"2021-09-15T16:08:23","date_gmt":"2021-09-15T20:08:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/"},"modified":"2021-09-15T16:08:23","modified_gmt":"2021-09-15T20:08:23","slug":"x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","title":{"rendered":"X4 Pharmaceuticals to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Sept.  15, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dTnXAWmDYEjLJKefxUO9sj6NBXgEYIaj7NmCA4-6bWzpihfJUIEbQdX9hkXhzMh7Ar3oAAB7bNmXYTrKmCEoBR6hKMtsgSUDzccmBw0wDgY=\" rel=\"nofollow noopener\" target=\"_blank\"><strong>X4 Pharmaceuticals, Inc.<\/strong><\/a> (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences &amp; MedTech Summit and participate in a fireside chat at the Cantor Global Healthcare Conference.<\/p>\n<p>\n        <strong>Details are as follows:<\/strong><br \/>\n        <br \/>Conference: Oppenheimer Fall Healthcare Life Sciences &amp; MedTech Summit<br \/>Date: Wednesday, September 22, 2021<br \/>Time: 11:35 a.m. ET<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=g14Z8XP5PfJaPLzhfjQBF6tfNYJtU_txNmQSX8OF6Q-CU7gVbXyD2la94KKhDwUFOl2leeqVdEvpIlg2koaZlpkWjr-KAz1XpW1AeCqmmQAxHKXEJrcep3Ig4kNmVgNptKKACNZDQEi5uGjtI4Fr_OKtGYlSccRqbhOVlQ9g0tlq7NZRIUUK1Dxny6HkJFYZK6VqPv2_cf-8jcyXx5N7O5pteM6q9u-7fIIyV7cWemhMw0Z8l5LTXe5Av_EUw0bU\" rel=\"nofollow noopener\" target=\"_blank\"><em>Presentation Webcast Link<\/em><\/a><\/p>\n<p>Conference: Cantor Global Healthcare Conference<br \/>Date: Thursday, September 30, 2021<br \/>Time: 10:00 a.m. ET<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hG8bxr1gYk_slqlp0_l7pgHzkKMvJAIlPbS1DLwxztan0iJXxM2e7FNlsfRMzh23emvF4acy039oQlixHLB8osgz5UGhoc32y-C2G7fmV56RxXF5VjYNf1Kmx2NLMbY1\" rel=\"nofollow noopener\" target=\"_blank\"><em>Fireside Chat Webcast Link<\/em><\/a><\/p>\n<p>Live webcasts of the Oppenheimer Fall Healthcare Life Sciences &amp; MedTech Summit and Cantor Global Healthcare Conference events will be available on the investors section of the X4 Pharmaceuticals\u2019 website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GS5E5YaQ0soLDiBxUrSZBUzCEFCNfzD9AvQlj6OH7rqXB7icvP0R_Oj4xA1GcATUkL6DqKLBn1njYUFBJkCSng==\" rel=\"nofollow noopener\" target=\"_blank\">www.x4pharma.com<\/a>. After the live webcasts, the events will remain archived on the X4 Pharmaceuticals\u2019 website for approximately 90 days.<\/p>\n<p>\n        <strong>About X4 Pharmaceuticals<\/strong><br \/>\n        <br \/>X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases of the immune system resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company\u2019s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a number of clinical trials, including a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials \u2013 in combination with ibrutinib in patients with Waldenstr\u00f6m\u2019s macroglobulinemia, and as monotherapy in patients with Severe Congenital Neutropenia and other chronic neutropenia disorders. X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GS5E5YaQ0soLDiBxUrSZBRAm-eIHdmDUMmX3B3tOV1oySo7n3nLBM9KMEg-ub7zALY8uW8q3_bONinWwuj0DQA==\" rel=\"nofollow noopener\" target=\"_blank\">www.x4pharma.com<\/a>.<\/p>\n<p>\n        <strong>Investors and Media:\u00a0<\/strong><br \/>\n        <br \/>Daniel Ferry<br \/>Managing Director <br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ove6W1aoeSEIUTskOgO4sLCRyrwjopo2a5TBs0dap0UcN8lXT8SZ6o43rZOAg3ZD2WPrMTZFr7ohfiEHMeUNueehXHaPbGlPQtjksy4Q5o_r2C4riD4W6snlkPM9AVOE\" rel=\"nofollow noopener\" target=\"_blank\">daniel@lifesciadvisors.com<\/a><br \/>(617) 430-7576<\/p>\n<p>M\u00f3nica Rouco Molina<br \/>Senior Account Executive <br \/>LifeSci Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cUGfNlkAIMEY4MPmUJSehanQnvdlsBk1jRmhxDRoZlIoIbmU9zYCYAOtk-6cPg6z-Yh1cvyepU4MkfQuoFxF75ysNlEnrvuhqUk7tU6lsTYlEpmM1qTs0INnyQ8Wqm8y\" rel=\"nofollow noopener\" target=\"_blank\">mroucomolina@lifescicomms.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMzQ5NiM0Mzk4NDMxIzUwMDA3MjE4MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDMxNDgyZGYtNzI3ZS00NjFkLThlYzktYmFjMTM3OWQyMTUxLTUwMDA3MjE4MQ==\/tiny\/X4-Pharmaceuticals.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) &#8212; X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences &amp; MedTech Summit and participate in a fireside chat at the Cantor Global Healthcare Conference. Details are as follows: Conference: Oppenheimer Fall Healthcare Life Sciences &amp; MedTech SummitDate: Wednesday, September 22, 2021Time: 11:35 a.m. ETPresentation Webcast Link Conference: Cantor Global Healthcare ConferenceDate: Thursday, September 30, 2021Time: 10:00 a.m. ETFireside Chat Webcast Link Live webcasts of the Oppenheimer Fall Healthcare Life Sciences &amp; MedTech Summit and Cantor Global Healthcare Conference &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;X4 Pharmaceuticals to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-538807","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>X4 Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"X4 Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) &#8212; X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences &amp; MedTech Summit and participate in a fireside chat at the Cantor Global Healthcare Conference. Details are as follows: Conference: Oppenheimer Fall Healthcare Life Sciences &amp; MedTech SummitDate: Wednesday, September 22, 2021Time: 11:35 a.m. ETPresentation Webcast Link Conference: Cantor Global Healthcare ConferenceDate: Thursday, September 30, 2021Time: 10:00 a.m. ETFireside Chat Webcast Link Live webcasts of the Oppenheimer Fall Healthcare Life Sciences &amp; MedTech Summit and Cantor Global Healthcare Conference &hellip; Continue reading &quot;X4 Pharmaceuticals to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-15T20:08:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMzQ5NiM0Mzk4NDMxIzUwMDA3MjE4MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"X4 Pharmaceuticals to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2021-09-15T20:08:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\"},\"wordCount\":392,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMzQ5NiM0Mzk4NDMxIzUwMDA3MjE4MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\",\"name\":\"X4 Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMzQ5NiM0Mzk4NDMxIzUwMDA3MjE4MQ==\",\"datePublished\":\"2021-09-15T20:08:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMzQ5NiM0Mzk4NDMxIzUwMDA3MjE4MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMzQ5NiM0Mzk4NDMxIzUwMDA3MjE4MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"X4 Pharmaceuticals to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"X4 Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"X4 Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) &#8212; X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences &amp; MedTech Summit and participate in a fireside chat at the Cantor Global Healthcare Conference. Details are as follows: Conference: Oppenheimer Fall Healthcare Life Sciences &amp; MedTech SummitDate: Wednesday, September 22, 2021Time: 11:35 a.m. ETPresentation Webcast Link Conference: Cantor Global Healthcare ConferenceDate: Thursday, September 30, 2021Time: 10:00 a.m. ETFireside Chat Webcast Link Live webcasts of the Oppenheimer Fall Healthcare Life Sciences &amp; MedTech Summit and Cantor Global Healthcare Conference &hellip; Continue reading \"X4 Pharmaceuticals to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-15T20:08:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMzQ5NiM0Mzk4NDMxIzUwMDA3MjE4MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"X4 Pharmaceuticals to Participate in Upcoming Investor Conferences","datePublished":"2021-09-15T20:08:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/"},"wordCount":392,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMzQ5NiM0Mzk4NDMxIzUwMDA3MjE4MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","name":"X4 Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMzQ5NiM0Mzk4NDMxIzUwMDA3MjE4MQ==","datePublished":"2021-09-15T20:08:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMzQ5NiM0Mzk4NDMxIzUwMDA3MjE4MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMzQ5NiM0Mzk4NDMxIzUwMDA3MjE4MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/x4-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"X4 Pharmaceuticals to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/538807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=538807"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/538807\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=538807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=538807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=538807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}